Nucleolin Recognizing Silica Nanoparticles Inhibit Cell Proliferation by Activating the Bax/Bcl-2/caspase-3 Signalling Pathway to Induce Apoptosis in Liver Cancer

Overview

Journal Front Pharmacol

Date 2023 Feb 27

PMID 36843953

Authors

Liangliang Xiang

Yun Li

Xinyu Gu

Shujie Li

Junwei Li

Jinlong Li

Yongxiang Yi

Affiliations

Soon will be listed here.

Abstract

Multifunctional nanocarrier platforms have shown great potential for the diagnosis and treatment of liver cancer. Here, a novel nucleolin-responsive nanoparticle platform was constructed for the concurrent detection of nucleolin and treatment of liver cancer. The incorporation of AS1411 aptamer, icaritin (ICT) and FITC into mesoporous silica nanoparticles, labelled as Atp-MSN (ICT@FITC) NPs, was the key to offer functionalities. The specific combination of the target nucleolin and AS1411 aptamer caused AS1411 to separate from mesoporous silica nanoparticles surface, allowing FITC and ICT to be released. Subsequently, nucleolin could be detected by monitoring the fluorescence intensity. In addition, Atp-MSN (ICT@FITC) NPs can not only inhibit cell proliferation but also improve the level of ROS while activating the Bax/Bcl-2/caspase-3 signalling pathway to induce apoptosis and . Moreover, our results demonstrated that Atp-MSN (ICT@FITC) NPs had low toxicity and could induce CD3 T-cell infiltration. As a result, Atp-MSN (ICT@FITC) NPs may provide a reliable and secure platform for the simultaneous identification and treatment of liver cancer.

Citing Articles

RNA-binding proteins as therapeutic targets in cancer.

Jungfleisch J, Gebauer F RNA Biol. 2025; 22(1):1-8.

PMID: 40016176 PMC: 11869776. DOI: 10.1080/15476286.2025.2470511.

Aptamer-functionalized nanomaterials (AFNs) for therapeutic management of hepatocellular carcinoma.

Yin X, Rong J, Shao M, Zhang S, Yin L, He Z J Nanobiotechnology. 2024; 22(1):243.

PMID: 38735927 PMC: 11089756. DOI: 10.1186/s12951-024-02486-5.

TfR Aptamer-Functionalized MSNs for Enhancing Targeted Cellular Uptake and Therapy of Cancer Cells.

Zhang J, Shang J, Tang X, Xu X ACS Omega. 2024; 8(51):48975-48983.

PMID: 38162791 PMC: 10753727. DOI: 10.1021/acsomega.3c06562.

References

Yu Y, Wang X, Jia X, Feng Z, Zhang L, Li H . Aptamer Probes Labeled with Lanthanide-Doped Carbon Nanodots Permit Dual-Modal Fluorescence and Mass Cytometric Imaging. Adv Sci (Weinh). 2021; 8(24):e2102812. PMC: 8693039. DOI: 10.1002/advs.202102812. View

Ouyang C, Zhang S, Xue C, Yu X, Xu H, Wang Z . Precision-Guided Missile-Like DNA Nanostructure Containing Warhead and Guidance Control for Aptamer-Based Targeted Drug Delivery into Cancer Cells in Vitro and in Vivo. J Am Chem Soc. 2020; 142(3):1265-1277. DOI: 10.1021/jacs.9b09782. View

Song H, Wang J, Xiong B, Hu J, Zeng P, Liu X . Biologically Safe, Versatile, and Smart Bismuthene Functionalized with a Drug Delivery System Based on Red Phosphorus Quantum Dots for Cancer Theranostics. Angew Chem Int Ed Engl. 2022; 61(22):e202117679. DOI: 10.1002/anie.202117679. View

He J, Peng T, Peng Y, Ai L, Deng Z, Wang X . Molecularly Engineering Triptolide with Aptamers for High Specificity and Cytotoxicity for Triple-Negative Breast Cancer. J Am Chem Soc. 2020; 142(6):2699-2703. DOI: 10.1021/jacs.9b10510. View

Chen D, Li B, Cai S, Wang P, Peng S, Sheng Y . Dual targeting luminescent gold nanoclusters for tumor imaging and deep tissue therapy. Biomaterials. 2016; 100:1-16. DOI: 10.1016/j.biomaterials.2016.05.017. View

Qin S, Li Q, Ming Xu J, Liang J, Cheng Y, Fan Y . Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival. Cancer Sci. 2020; 111(11):4218-4231. PMC: 7648021. DOI: 10.1111/cas.14641. View

Li H, Liu Y, Jiang W, Xue J, Cheng Y, Wang J . Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma. BMC Cancer. 2021; 21(1):318. PMC: 7992931. DOI: 10.1186/s12885-021-08043-9. View

Wu T, Liu Y, Cao Y, Liu Z . Engineering Macrophage Exosome Disguised Biodegradable Nanoplatform for Enhanced Sonodynamic Therapy of Glioblastoma. Adv Mater. 2022; 34(15):e2110364. DOI: 10.1002/adma.202110364. View

Llovet J, Castet F, Heikenwalder M, Maini M, Mazzaferro V, Pinato D . Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2021; 19(3):151-172. DOI: 10.1038/s41571-021-00573-2. View

10.

Guo J, Zeng H, Shi X, Han T, Liu Y, Liu Y . A CFH peptide-decorated liposomal oxymatrine inactivates cancer-associated fibroblasts of hepatocellular carcinoma through epithelial-mesenchymal transition reversion. J Nanobiotechnology. 2022; 20(1):114. PMC: 8898522. DOI: 10.1186/s12951-022-01311-1. View

11.

Dad H, Gu T, Zhu A, Huang L, Peng L . Plant Exosome-like Nanovesicles: Emerging Therapeutics and Drug Delivery Nanoplatforms. Mol Ther. 2020; 29(1):13-31. PMC: 7791080. DOI: 10.1016/j.ymthe.2020.11.030. View

12.

Wu X, Yang H, Chen X, Gao J, Duan Y, Wei D . Nano-herb medicine and PDT induced synergistic immunotherapy for colon cancer treatment. Biomaterials. 2021; 269:120654. DOI: 10.1016/j.biomaterials.2021.120654. View

13.

Missiaen R, Anderson N, Kim L, Nance B, Burrows M, Skuli N . GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. Cell Metab. 2022; 34(8):1151-1167.e7. PMC: 9357184. DOI: 10.1016/j.cmet.2022.06.010. View

14.

Zhang Z, Deng Q, Xiao C, Li Z, Yang X . Rational Design of Nanotherapeutics Based on the Five Features Principle for Potent Elimination of Cancer Stem Cells. Acc Chem Res. 2022; 55(4):526-536. DOI: 10.1021/acs.accounts.1c00635. View

15.

Semcheddine F, Guissi N, Liu W, Tayyaba , Gang L, Jiang H . Rapid and label-free cancer theranostics bio-self-assembled DNA-gold nanostructures loaded exosomes. Mater Horiz. 2021; 8(10):2771-2784. DOI: 10.1039/d1mh00880c. View

16.

Costoya J, Surnar B, Kalathil A, Kolishetti N, Dhar S . Controlled release nanoplatforms for three commonly used chemotherapeutics. Mol Aspects Med. 2021; 83:101043. PMC: 10074549. DOI: 10.1016/j.mam.2021.101043. View

17.

Liu Q, Wang C, Zheng Y, Zhao Y, Wang Y, Hao J . Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR/Cas9-based cancer immunotherapy. Biomaterials. 2020; 258:120275. DOI: 10.1016/j.biomaterials.2020.120275. View

18.

Qian R, Ding L, Ju H . Switchable fluorescent imaging of intracellular telomerase activity using telomerase-responsive mesoporous silica nanoparticle. J Am Chem Soc. 2013; 135(36):13282-5. DOI: 10.1021/ja406532e. View

19.

Wang C, Wu P, Shi J, Jiang Z, Wei X . Synthesis and cancer cell growth inhibitory activity of icaritin derivatives. Eur J Med Chem. 2015; 100:139-50. DOI: 10.1016/j.ejmech.2015.06.006. View

20.

Vallet-Regi M, Schuth F, Lozano D, Colilla M, Manzano M . Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?. Chem Soc Rev. 2022; 51(13):5365-5451. PMC: 9252171. DOI: 10.1039/d1cs00659b. View